Amyl Therapeutics

About Amyl Therapeutics

Amyl Therapeutics is a preclinical-stage biotechnology company founded in November 2020 by Dr. Florent Gros and Dr. Pierre Vandepapelière. Based in Liège, Belgium, the company is focused on developing treatments for diseases caused by amyloid protein misfolding, such as systemic amyloidosis and neurodegenerative conditions like Alzheimer's and Parkinson's.

The company's core technology is a platform called Pan-Amyloid Immunotherapy (PAI), formerly known as ClariTY, which develops therapies that can bind to the common structural fold shared by all amyloid fibrils. This approach differs from therapies that target only a single type of misfolded protein, allowing Amyl Therapeutics' candidates to potentially neutralize multiple toxic protein aggregates at once, including amyloid-beta, tau, and alpha-synuclein. The therapies are designed to clear existing aggregates, prevent further accumulation, and block the cell-to-cell spread of these proteins.

The co-founder, CEO, and CMO, Dr. Pierre Vandepapelière, has over 30 years of experience in vaccine and biological therapeutics development at companies like GSK and previously led Imcyse as CEO. The company's business model is centered on the discovery and preclinical development of its therapeutic candidates with the goal of moving them into clinical trials. The initial focus is on AL amyloidosis, a rare systemic disease, with plans to expand into neurodegenerative diseases. The company is preparing for a Phase I trial for its lead candidate, expected to begin in 2025.

Amyl Therapeutics has secured significant funding to advance its pipeline. In June 2021, it closed a Series A round of €18.3 million ($22.3 million), which included equity and non-dilutive funding. It received an additional €5 million in November 2023. These funds are being used to generate preclinical proof-of-concept for its lead candidates and prepare for clinical development.